{"id":11084,"date":"2023-08-02T00:00:00","date_gmt":"2023-08-02T05:00:00","guid":{"rendered":"https:\/\/myeloma.ca\/1970\/01\/01\/sante-canada-a-emis-un-avis-de-conformite-avec-conditions-ac-c-pour-ladministration-de-tecvayli-injection-de-teclistamab\/"},"modified":"2025-08-19T08:28:10","modified_gmt":"2025-08-19T13:28:10","slug":"sante-canada-a-emis-un-avis-de-conformite-avec-conditions-ac-c-pour-ladministration-de-tecvayli-injection-de-teclistamab","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2023\/08\/02\/sante-canada-a-emis-un-avis-de-conformite-avec-conditions-ac-c-pour-ladministration-de-tecvayli-injection-de-teclistamab\/","title":{"rendered":"SANT\u00c9\u00a0CANADA A \u00c9MIS UN AVIS DE CONFORMIT\u00c9 AVEC CONDITIONS (AC-C) POUR L’ADMINISTRATION DE TECVAYLI\u2122 (INJECTION DE TECLISTAMAB)"},"content":{"rendered":"

Janssen Pharmaceutical Companies of Johnson & Johnson a annonc\u00e9 aujourd’hui que Sant\u00e9 Canada a \u00e9mis un avis de conformit\u00e9 avec conditions (AC-C) pour l’administration de TECVAYLI\u2122 (injection de teclistamab) dans le traitement des patients adultes atteints d’un my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire, qui ont fait l’objet d’au moins trois intentions de traitement ant\u00e9rieures, et dont la maladie a progress\u00e9 lors du dernier traitement. Les intentions de traitement ant\u00e9rieures comprenaient un inhibiteur du prot\u00e9asome, un agent immunomodulateur et un anticorps monoclonal anti-CD382. Le teclistamab est un anticorps bisp\u00e9cifique qui cible le r\u00e9cepteur CD3 exprim\u00e9 \u00e0 la surface des lymphocytes T et l’antig\u00e8ne de maturation des lymphocytes B (BCMA) exprim\u00e9 \u00e0 la surface des cellules de my\u00e9lome multiple. <\/p>\n

Lire le communiqu\u00e9<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Janssen Pharmaceutical Companies of Johnson & Johnson a annonc\u00e9 aujourd’hui que Sant\u00e9 Canada a \u00e9mis un avis de conformit\u00e9 avec conditions (AC-C) pour l’administration de TECVAYLI\u2122 (injection de teclistamab) dans le traitement des patients adultes atteints d’un my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire, qui ont fait l’objet d’au moins trois intentions de traitement ant\u00e9rieures, et dont la maladie […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[53,50,58,52],"tags":[],"class_list":["post-11084","post","type-post","status-publish","format-standard","hentry","category-actualites-et-evenement","category-news-events","category-nouvelles-de-myelome-canada","category-whats-new-at-myeloma-canada"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11084","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=11084"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11084\/revisions"}],"predecessor-version":[{"id":31255,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11084\/revisions\/31255"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=11084"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=11084"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=11084"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}